TheFly.com
LYEL
Lyell Immunopharma
$
()
Lyell Immunopharma files $400M mixed securities shelf
Lyell Immunopharma price target lowered by $2 at H.C. Wainwright, here's why
Lyell Immunopharma announces Orphan Drug Designation for LYL845
Lyell Immunopharma price target lowered to $8 from $9 at H.C. Wainwright
Lyell Immunopharma treatment of Stage IIB-IV melanoma granted orphan status
Lyell Immunopharma is presenting nonclinical data at SITC on LYL119
Lyell Immunopharma to evaluate Cellares' automated manufacturing platform
Lyell, Cellares to evaluate automated manufacturing of its CAR T-Cell Therapy
Lyell Immunopharma downgraded to Neutral from Overweight at JPMorgan
Lyell Immunopharma reports Q2 net loss $45.6M vs. Q2 net loss $10.3M last year
Lyell Immunopharma says Matthew Lang, J.D. has joined as Chief Business Officer
Lyell Immunopharma reports Q1 net loss $67M vs. $68.1M last year
Copyright ©1998-2024 Thefly.com LLC
